Vaccine Safety Registry
DTaP and Tdap Vaccine Safety
Institutional safety data for DTaP, Tdap, and Td vaccines. Clinical monitoring, manufacturer packages, and adverse event profiles.
Open Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Diphtheria, tetanus, and pertussis are high-impact bacterial pathologies. Prior to the established registry of vaccines, these diseases represented significant morbidity and mortality rates within the United States pediatric population.
Contemporary immunization protocols have successfully suppressed disease transmission. DTaP remains the standard for primary series protection, while Tdap and Td serve as critical maintenance boosters for adolescents and adults.
Vaccine Formulations
Module specifics & formulations
Formulation Node
DTaP: Pediatric Protocol
Ages: 6 weeks - 6 years
- Daptacel (Sanofi)
- Infanrix (GSK)
Formulation Node
Tdap: Adolescent/Adult Boosters
Low-antigen maintenance
- Adacel (Sanofi)
- Boostrix (GSK)
Adverse Events
Reported reactions & surveillance
Pediatric (DTaP) Effects
- Localized erythema
- Pyrexia
- Irritability/fussiness
- Lethargy
Adult (Tdap/Td) Effects
- Injection site pain
- Cephalalgia (Headache)
- Generalized fatigue
- GI distress
Surveillance Analytics
Post-market surveillance metrics
80+ Years
Safety Monitoring Data
< 1 / 1M
Severe Allergic Reaction
Institutional Synthesis
Decades of surveillance and millions of successfully synchronized doses confirm an exemplary safety profile across all pediatric and adult demographic cohorts.
Editorial Governance
Clinical Reviewers & Authors
Dr. Ritu Saxena
MBBS, MD (Community Medicine), MPH
Public Health & Preventive Medicine
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the ACIP
MMWR Recommendations and Reports, 67(2):1-44
- 2WHO2024Pertussis vaccines: WHO position paper — August 2015
Weekly Epidemiological Record, 90(35):433-460
- 3FDA2024DAPTACEL, INFANRIX, ADACEL, and BOOSTRIX Package Inserts & Post-Licensure Reviews
U.S. Food and Drug Administration CBER Biologics
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Aditya Kumar and clinically reviewed by Dr. Ritu Saxena, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.